HGH Fragment 176-191 vs Livagen
Side-by-side comparison of key properties, dosing, and research.
Fat Loss & Metabolic
HGH Fragment 176-191Anti-Aging & Longevity
Livagen- Summary
- HGH Fragment 176-191 (also known as AOD-9604) is a stabilized, modified fragment of the human growth hormone molecule corresponding to amino acids 176–191 with an addition of a tyrosine residue at the N-terminus. It retains HGH's fat-burning properties without the anabolic, diabetogenic, or IGF-1-stimulating effects.
- Livagen is a dipeptide bioregulator (Lys-Glu) developed by Professor Vladimir Khavinson, tissue-specific for the liver and thymus. It supports hepatocyte function, promotes liver cell regeneration, and modulates immune function via thymic activity. Research suggests benefits in chronic liver disease, hepatic aging, and immune restoration following liver damage.
- Half-Life
- ~30 minutes
- Short (minutes); gene-regulatory effects are sustained
- Admin Route
- SubQ
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 250–500 mcg
- 10 mg per day
- Frequency
- 1–3 times daily
- Daily for 10–30 days
- Key Benefits
- Selective fat burning without anabolic side effects
- Reduces visceral and subcutaneous fat
- No insulin resistance or blood glucose disruption
- Does not stimulate IGF-1
- May support cartilage and bone repair (at higher doses)
- No effect on growth or organ size
- Supports hepatocyte regeneration and liver tissue repair
- Normalizes liver cell protein synthesis
- Immune modulation via thymic activity
- Potential benefits in chronic hepatitis and liver aging
- Anti-aging effects on hepatic tissue
- May support liver recovery after toxic insult or alcohol damage
- Complementary to NAD+ and glutathione in liver health protocols
- Side Effects
- Injection site irritation
- Temporary lethargy
- Headache (rare)
- Nausea (rare)
- Generally well tolerated
- Mild injection site reactions
- No significant hepatotoxic effects reported at standard doses
- Stacks With
- —
- —